financetom
Business
financetom
/
Business
/
ONEOK fourth-quarter profit rises on higher demand, expects higher 2025 earnings
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ONEOK fourth-quarter profit rises on higher demand, expects higher 2025 earnings
Feb 25, 2025 10:23 AM

Feb 24 (Reuters) - Pipeline operator ONEOK ( OKE ) forecast annual income growth of

about 11% and reported a 34.2% rise in fourth-quarter profit on Monday, helped by higher demand

and accretive contributions from the EnLink acquisition.

In November, the company said it would buy the remaining shares of EnLink Midstream for $4.3

billion, following its acquisition of a 43% controlling interest in the peer from Global

Infrastructure Partners for about $3.3 billion.

The company also reported a 3% growth in the Rocky Mountain region natural gas liquids (NGL)

raw feed throughput volumes and a 4% increase in crude oil volume shipped.

Its quarterly core profit from the NGL segment was up 13.5% at $696 million from a year

earlier, while its quarterly core profit from the refined products and crude segment was up

42.2% at $603 million.

The company, on a conference call on Tuesday, said its natural gas pipeline segment's assets

are well positioned to benefit from industrial demand growth driven by data centers, LNG exports

and ammonia facilities.

The increasing popularity of advanced artificial intelligence tools, such as OpenAI's

ChatGPT, has been driving the need for high-performance data centers capable of processing vast

amounts of data, boosting demand for electricity.

"Our newly acquired assets in Louisiana provide direct connectivity to major LNG exporters

and industrial customers. They are off to approximately 30 potential power plant expansion

projects across our footprint," a company executive said on the conference call.

The company now expects current-year net income between $3.21 billion and $3.69 billion, the

midpoint of which was up about 11% from last year. It also expects annual capital expenditure

between $2.8 billion and $3.2 billion.

The Tulsa, Oklahoma-based company reported net income attributable of $923 million, or $1.57

per share, for the quarter ended December 31, compared with $688 million, or $1.18 per share, a

year earlier.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Oculis Holding Files $300 Million Mixed-Securities Shelf Registration
Oculis Holding Files $300 Million Mixed-Securities Shelf Registration
Apr 1, 2024
02:12 PM EDT, 04/01/2024 (MT Newswires) -- Oculis Holding ( OCS ) on Monday filed a registration with the US Securities and Exchange Commission to sell ordinary shares, debt securities, warrants, and units which it plans to offer from time to time. The mixed-securities are expected to have an aggregate offering price of up to $300 million, the company said....
Xtant Medical Files $150 Million Mixed Shelf; Shares Fall
Xtant Medical Files $150 Million Mixed Shelf; Shares Fall
Apr 1, 2024
02:15 PM EDT, 04/01/2024 (MT Newswires) -- Xtant Medical Holdings ( XTNT ) shares fell almost 12% in recent Monday trading after the company filed a registration statement with the US Securities and Exchange Commission covering the potential sale of up to $150 million of its securities from time to time in one or more offerings. The filing covers common...
Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label
Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label
Apr 1, 2024
02:04 PM EDT, 04/01/2024 (MT Newswires) -- Solid Biosciences ( SLDB ) said Monday its gene therapy candidate SGT-003 for Duchenne muscular dystrophy has received rare pediatric disease designation from the US Food and Drug Administration. The designation is designed to encourage development of therapies that target rare pediatric disease and could result in the granting of a priority review...
BioSyent To Present At LD Micro New York Investor Conference
BioSyent To Present At LD Micro New York Investor Conference
Apr 1, 2024
02:12 PM EDT, 04/01/2024 (MT Newswires) -- BioSyent ( BIOYF ) on Monday said chief executive Rene Goehrum will be presenting in person at the LD Micro Invitational XIV Conference in New York City on Tuesday, April 9 at 8 am EDT. This presentation will also be live-streamed virtually. Goehrum will also be available to meet with investors on a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved